磷酸肌酸联合灯盏花素治疗病毒性心肌炎67例临床研究
|
摘要
目的探讨磷酸肌酸联合灯盏花素注射液治疗病毒性心肌炎的临床疗效及其作用机制。方法将134例病毒性心肌炎患者随机分为对照组和观察组,各67例。对照组患者给予常规治疗+磷酸肌酸治疗,观察组患者在对照组患者治疗基础上加用灯盏花素注射液治疗,疗程均为2周。结果治疗后,两组患者肿瘤坏死因子-α(TNF-α)、白细胞介素6(IL-6)、白细胞介素17(IL-17)、肌酸激酶同工酶(CK-MB)、肌钙蛋白(c Tn T)、丙二醛(MDA)水平均显著降低(P<0.05),且观察组显著低于对照组同期(P<0.05);两组患者治疗后的白细胞介素35(IL-35)和超氧化物歧化酶(SOD)水平均显著升高(P<0.05),且观察组显著高于对照组同期(P<0.05);观察组总有效率显著高于对照组(94.03%比80.60%,P<0.05)。结论磷酸肌酸联合灯盏花素注射液治疗病毒性心肌炎,可调节免疫平衡,减轻炎症损伤,降低氧化应激反应,减少心肌损伤,提高临床疗效,值得临床推广。
Objective To investigate the clinical effect of creatine phosphate combined with Breviscapine Injection in the treatment of viral myocarditis and its mechanism of action. Methods Totally 134 patients with viral myocarditis were randomly divided into the control group and the observation group,67 cases in each group. The control group was given conventional treatment combined with creatine phosphate,on this basis,the observation group was given Breviscapine Injection,the course of treatment was 2 weeks. Results After treatment,the levels of TNF-α,IL-6,IL-17,CK-MB,c Tn T and MDA were significantly lower than those before treatment,and those in the observation group were significantly lower than those in the control group in the same period( P < 0. 05). After treatment,the levels of IL-35 and SOD were significantly higher than those before treatment,and those in the observation group were significantly higher than those in the control group in the same period( P < 0. 05). The total effective rate of the observation group was significantly higher than that of the control group( 94. 03% vs. 80. 60%,P < 0. 05). Conclusion Creatine phosphate combined with Breviscapine Injection in the treatment of viral myocarditis can regulate immune balance,reduce inflammatory injury,oxidative stress response and myocardial injury,it also can improve the clinical efficacy,which is worthy of clinical promotion.
Objective To investigate the clinical effect of creatine phosphate combined with Breviscapine Injection in the treatment of viral myocarditis and its mechanism of action. Methods Totally 134 patients with viral myocarditis were randomly divided into the control group and the observation group,67 cases in each group. The control group was given conventional treatment combined with creatine phosphate,on this basis,the observation group was given Breviscapine Injection,the course of treatment was 2 weeks. Results After treatment,the levels of TNF-α,IL-6,IL-17,CK-MB,c Tn T and MDA were significantly lower than those before treatment,and those in the observation group were significantly lower than those in the control group in the same period( P < 0. 05). After treatment,the levels of IL-35 and SOD were significantly higher than those before treatment,and those in the observation group were significantly higher than those in the control group in the same period( P < 0. 05). The total effective rate of the observation group was significantly higher than that of the control group( 94. 03% vs. 80. 60%,P < 0. 05). Conclusion Creatine phosphate combined with Breviscapine Injection in the treatment of viral myocarditis can regulate immune balance,reduce inflammatory injury,oxidative stress response and myocardial injury,it also can improve the clinical efficacy,which is worthy of clinical promotion.
引文
[1]丁国斌.益气复脉汤配合西医治疗病毒性心肌炎疗效及对血清心肌酶的影响[J].现代中西医结合杂志,2016,25(35):3959-3961.
[2]张骏,罗晓丽,杨小利,等.芪冬颐心口服液治疗老年病毒性心肌炎临床研究[J].中国药业,2017,26(4):32-35.
[3]林元涛,曾晓玲,陈亮,等.磷酸肌酸钠联合卡托普利治疗儿童病毒性心肌炎的疗效观察[J].中国基层医药,2015,22(12):1823-1825.
[4]于学江.灯盏花素对糖尿病心肌病大鼠血清NO、ET-1及心肌细胞凋亡的影响[J].中国现代药物应用,2017,11(15):197-198.
[5]付生弟,谢辉,邹昌群.灯盏花素注射液联合参麦注射液辅助治疗对病毒性心肌炎的临床疗效及机制研究[J].医学综述,2016,22(7):1424-1426.
[6]吴铁吉.病毒性心肌炎诊断标准(修订草案)[J].中国实用儿科杂志,2000,15(5):315.
[7]中华心血管病杂志编辑委员会心肌炎心肌病对策专题组.关于成人急性病毒性心肌炎诊断参考标准和采纳世界卫生组织国际心脏病学联合会工作组关于心肌病定义和分类的意见[J].中国循环杂志,2001,16(4):307-308.
[8]王吉佳,赵悦,李晶瑶,等.益气舒心丸治疗病毒性心肌炎的效果和可能机制[J].中国生化药物杂志,2016,36(8):91-93.
[9]曹永,徐侠,张培影.五参二连颗粒对病毒性心肌炎病人血清IL-6、TNF-α及c Tn I水平的影响[J].中西医结合心脑血管病杂志,2016,14(19):2213-2215.
[10]陈锐,陈艳清,贾建,等.病毒性心肌炎患者外周血中TNF-α、TGF-β1和IFN-γ细胞因子水平的分析[J].国际检验医学杂志,2016,37(8):1119-1120.
[11]石宏云,冯伟.白细胞介素-17A在病毒性心肌炎小鼠心肌表达的意义[J].中华实用儿科临床杂志,2014,29(1):45-47.
[12]张传峰,苑海涛.病毒性心肌炎患者血清IL17、IL35水平变化及意义[J].山东医药,2014,54(31):28-30.
[13]刘艳宾,贾新萍,秦洁洁,等.病毒性心肌炎患者治疗前后血清IL-35水平的变化及其意义[J].中国现代医学杂志,2017,27(6):123-126.
[14]赵振霞,赵振敏,李彤.黄芪注射液对病毒性心肌炎患者氧化应激和炎性反应影响[J].中国实验方剂学杂志,2015,21(23):176-179.
[15]赵晓宇,曹妍,孙鹤,等.氧化应激与病毒性心肌炎[J].现代生物医学进展,2015,15(4):785-787.
[16]施伟林,陈茜.灯盏花素联合补气祛瘀中药治疗AECOPD疗效及对免疫球蛋白、氧化应激指标的影响[J].中国中医急症,2017,26(5):929-931.
[17]顾熙东,章晓鹰,徐金龙,等.病毒性心肌炎患者血清CKMB、hs-CRP、IL-35及c Tn I水平的表达[J].现代生物医学进展,2017,17(6):1109-1101.
[18]袁尉峰,赵新湘.急性病毒性心肌炎心脏磁共振心肌首过灌注及与c Tn T的相关性[J].临床心血管病杂志,2017,33(6):539-543.
[2]张骏,罗晓丽,杨小利,等.芪冬颐心口服液治疗老年病毒性心肌炎临床研究[J].中国药业,2017,26(4):32-35.
[3]林元涛,曾晓玲,陈亮,等.磷酸肌酸钠联合卡托普利治疗儿童病毒性心肌炎的疗效观察[J].中国基层医药,2015,22(12):1823-1825.
[4]于学江.灯盏花素对糖尿病心肌病大鼠血清NO、ET-1及心肌细胞凋亡的影响[J].中国现代药物应用,2017,11(15):197-198.
[5]付生弟,谢辉,邹昌群.灯盏花素注射液联合参麦注射液辅助治疗对病毒性心肌炎的临床疗效及机制研究[J].医学综述,2016,22(7):1424-1426.
[6]吴铁吉.病毒性心肌炎诊断标准(修订草案)[J].中国实用儿科杂志,2000,15(5):315.
[7]中华心血管病杂志编辑委员会心肌炎心肌病对策专题组.关于成人急性病毒性心肌炎诊断参考标准和采纳世界卫生组织国际心脏病学联合会工作组关于心肌病定义和分类的意见[J].中国循环杂志,2001,16(4):307-308.
[8]王吉佳,赵悦,李晶瑶,等.益气舒心丸治疗病毒性心肌炎的效果和可能机制[J].中国生化药物杂志,2016,36(8):91-93.
[9]曹永,徐侠,张培影.五参二连颗粒对病毒性心肌炎病人血清IL-6、TNF-α及c Tn I水平的影响[J].中西医结合心脑血管病杂志,2016,14(19):2213-2215.
[10]陈锐,陈艳清,贾建,等.病毒性心肌炎患者外周血中TNF-α、TGF-β1和IFN-γ细胞因子水平的分析[J].国际检验医学杂志,2016,37(8):1119-1120.
[11]石宏云,冯伟.白细胞介素-17A在病毒性心肌炎小鼠心肌表达的意义[J].中华实用儿科临床杂志,2014,29(1):45-47.
[12]张传峰,苑海涛.病毒性心肌炎患者血清IL17、IL35水平变化及意义[J].山东医药,2014,54(31):28-30.
[13]刘艳宾,贾新萍,秦洁洁,等.病毒性心肌炎患者治疗前后血清IL-35水平的变化及其意义[J].中国现代医学杂志,2017,27(6):123-126.
[14]赵振霞,赵振敏,李彤.黄芪注射液对病毒性心肌炎患者氧化应激和炎性反应影响[J].中国实验方剂学杂志,2015,21(23):176-179.
[15]赵晓宇,曹妍,孙鹤,等.氧化应激与病毒性心肌炎[J].现代生物医学进展,2015,15(4):785-787.
[16]施伟林,陈茜.灯盏花素联合补气祛瘀中药治疗AECOPD疗效及对免疫球蛋白、氧化应激指标的影响[J].中国中医急症,2017,26(5):929-931.
[17]顾熙东,章晓鹰,徐金龙,等.病毒性心肌炎患者血清CKMB、hs-CRP、IL-35及c Tn I水平的表达[J].现代生物医学进展,2017,17(6):1109-1101.
[18]袁尉峰,赵新湘.急性病毒性心肌炎心脏磁共振心肌首过灌注及与c Tn T的相关性[J].临床心血管病杂志,2017,33(6):539-543.